Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience
Waissengrin et al.·Journal of Pain and Symptom ManagementImpact 0.8
GemischtGRADENiedrig81 Zitate
Stichproben = 279 Pat.
DauerMindestens 6 Monate…
EndpunktPatientenberichtete…
Verblindungn.a.
DesignRetrospektive Beobachtungsstudie
Cannabinoidvollspektrum
”Kernaussage
Patienten berichteten Verbesserungen bei Schmerz (70%), Allgemeinbefinden (70%), Appetit (60%) und Übelkeit (50%), aber nur 46% der nach 6 Monaten noch lebenden Patienten erneuerten ihre Permit; Nebenwirkungen waren mild (Fatigue, Schwindel).
Zusammenfassung
Retrospektive Studie zu medizinischem Cannabis bei n=279 israelischen Krebs-Patienten (84% metastasiert); von n=113 Nutzern nach 1 Monat berichteten 70% Verbesserung bei Schmerz, 70% bei Allgemeinbefinden, 60% bei Appetit, 50% bei Übelkeit. Nebenwirkungen mild (Fatigue, Schwindel). Von n=151 nach 6 Monaten lebenden Patienten erneuerten 46% die Cannabis-Genehmigung.
InterventionMedizinisches Cannabis (Indikationen: Schmerz, Übelkeit, Appetitverlust u.a.), Applikationsform und Dosis nicht spezifiziert
O
Outcome70% berichteten Verbesserung bei Schmerz und allgemeinem Wohlbefinden, 60% bei Appetit, 50% bei Übelkeit; Nebenwirkungen mild (Fatigue, Schwindel)
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Context: The use of the cannabis plant (Cannabis sativa L.) for the palliative treatment of cancer patients has been legalized in multiple jurisdictions including Israel. Yet, not much is currently known regarding the efficacy and patterns of use of cannabis in this setting.
Objectives: To analyze the indications for the administration of cannabis among adult Israeli cancer patients and evaluate its efficacy.
Methods: Efficacy and patterns of use of cannabis were evaluated using physician-completed application forms, medical files, and a detailed questionnaire in adult cancer patients treated at a single institution.
Results: Of approximately 17,000 cancer patients seen, 279 (<1.7%) received a permit for cannabis from an authorized institutional oncologist. The median age of cannabis users was 60 years (range 19-93 years), 160 (57%) were female, and 234 (84%) had metastatic disease. Of 151 (54%) patients alive at six months, 70 (46%) renewed their cannabis permit. Renewal was more common among younger patients and those with metastatic disease. Of 113 patients alive and using cannabis at one month, 69 (61%) responded to the detailed questionnaire. Improvement in pain, general well-being, appetite, and nausea were reported by 70%, 70%, 60%, and 50%, respectively. Side effects were mild and consisted mostly of fatigue and dizziness.
Conclusion: Cannabis use is perceived as highly effective by some patients with advanced cancer and its administration can be regulated, even by local authorities. Additional studies are required to evaluate the efficacy of cannabis as part of the palliative treatment of cancer patients.